Evidence map›Paper›PMID 25082828›Full record

ArticleHuman molecular genetics2014

Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting.

Kristy Swiderski, Scott A Shaffer, Byron Gallis, Guy L Odom, Andrea L Arnett, J Scott Edgar, Dale M Baum, Annabel Chee, Timur Naim, Paul Gregorevic and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Cytoplasmic region of beta-dystroglycan is essential for postsynaptic maturation and neuromuscular function in mice.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Kristy SwiderskiBasic and Clinical Myology Laboratory, Department of Physiology, University of Melbourne, VIC 3010, Australia Department of Neurology, University of Washington School of Medicine, Seattle, WA 98195-7720, USA.
Scott A ShafferDepartment of Medicinal Chemistry, University of Washington School of Medicine, Seattle, WA 98195-7610, USA.
Byron GallisDepartment of Medicinal Chemistry, University of Washington School of Medicine, Seattle, WA 98195-7610, USA.
Guy L OdomDepartment of Neurology, University of Washington School of Medicine, Seattle, WA 98195-7720, USA.
Andrea L ArnettDepartment of Neurology, University of Washington School of Medicine, Seattle, WA 98195-7720, USA.
J Scott EdgarDepartment of Medicinal Chemistry, University of Washington School of Medicine, Seattle, WA 98195-7610, USA.
Dale M BaumBasic and Clinical Myology Laboratory, Department of Physiology, University of Melbourne, VIC 3010, Australia.
Annabel CheeBasic and Clinical Myology Laboratory, Department of Physiology, University of Melbourne, VIC 3010, Australia.
Timur NaimBasic and Clinical Myology Laboratory, Department of Physiology, University of Melbourne, VIC 3010, Australia.
Paul GregorevicMuscle Biology and Therapeutics Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Kate T MurphyBasic and Clinical Myology Laboratory, Department of Physiology, University of Melbourne, VIC 3010, Australia.
James MoodyDepartment of Biochemistry, University of Washington School of Medicine, Seattle, WA 98195-7350, USA and Program in Molecular and Cellular Biology, University of Washington School of Medicine, Seattle, WA 98195-7275, USA.
David R GoodlettDepartment of Medicinal Chemistry, University of Washington School of Medicine, Seattle, WA 98195-7610, USA.
Gordon S LynchBasic and Clinical Myology Laboratory, Department of Physiology, University of Melbourne, VIC 3010, Australia.
Jeffrey S ChamberlainDepartment of Neurology, University of Washington School of Medicine, Seattle, WA 98195-7720, USA Department of Biochemistry, University of Washington School of Medicine, Seattle, WA 98195-7350, USA and Program in Molecular and Cellular Biology, University of Washington School of Medicine, Seattle, WA 98195-7275, USA jsc5@uw.edu.
University of Melbourne · AUUniversity of Washington · USBaker Heart and Diabetes Institute · AU

Funding

University of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4M
TrainingP41GM103533 · NIGMS · UNIVERSITY OF WASHINGTON · PI MACCOSS, MICHAEL · 2012 to 2021
$20.7M
Assembly of the Dystrophin-Glycoprotein ComplexR01AR044533 · NIAMS · UNIVERSITY OF WASHINGTON · PI CHAMBERLAIN, JEFFREY S · 1997 to 2021
$8.9M
DYSTROPHIN REPLACEMENT IN MDX MICER01AR040864 · NIAMS · UNIVERSITY OF WASHINGTON · PI JEFFREY S CHAMBERLAIN · 1991 to 2026
$8.8M
Dystrophin Replacement in mdx miceR37AR040864 · NIAMS · UNIVERSITY OF WASHINGTON · PI CHAMBERLAIN, JEFFREY S · 2005 to 2014
$5.0M
Signaling Mechanisms of the Dystrophin-Glycoprotein ComplexF30NS068005 · NINDS · UNIVERSITY OF WASHINGTON · PI ARNETT, ANDREA · 2010 to 2012
$117k
NIAMS NIH HHS AR40864NIAMS NIH HHS AR44533NIAMS NIH HHS R01 AR040864NIAMS NIH HHS R01 AR044533NIGMS NIH HHS GM103533NIGMS NIH HHS P41 GM103533NIGMS NIH HHS T32 GM007266NINDS NIH HHS F30 NS068005NINDS NIH HHS F30NS068005
6 · The paper itself

Abstract

Mutations in dystrophin lead to Duchenne muscular dystrophy, which is among the most common human genetic disorders. Dystrophin nucleates assembly of the dystrophin-glycoprotein complex (DGC), and a defective DGC disrupts an essential link between the intracellular cytoskeleton and the basal lamina, leading to progressive muscle wasting. In vitro studies have suggested that dystrophin phosphorylation may affect interactions with actin or syntrophin, yet whether this occurs in vivo or affects protein function remains unknown. Utilizing nanoflow liquid chromatography mass spectrometry, we identified 18 phosphorylated residues within endogenous dystrophin. Mutagenesis revealed that phosphorylation at S3059 enhances the dystrophin-dystroglycan interaction and 3D modeling utilizing the Rosetta software program provided a structural model for how phosphorylation enhances this interaction. These findings demonstrate that phosphorylation is a key mechanism regulating the interaction between dystrophin and the DGC and reveal that posttranslational modification of a single amino acid directly modulates the function of dystrophin.

Indexed as

Amino Acid SequenceAnimalsCell DifferentiationCell LineCysteineDystroglycansDystrophinDystrophin-Associated ProteinsGene Expression RegulationHEK293 CellsHumansMiceMice, Inbred C57BLMice, Inbred mdxModels, MolecularMolecular Sequence DataCysteineDystroglycansDystrophinDystrophin-Associated ProteinsRecombinant Fusion ProteinsSerinesyntrophin

Identifiers

PMID25082828
PMCPMC4245040
OpenAlexW2142193698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.